Pharmanutra SpA
MIL:PHN
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Walmart Inc
NYSE:WMT
|
Retail
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
45.45
63.1
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
UnitedHealth Group Inc
NYSE:UNH
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Walmart Inc
NYSE:WMT
|
US | |
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one PHN stock under the Base Case scenario is 42.79 EUR. Compared to the current market price of 54 EUR, Pharmanutra SpA is Overvalued by 21%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation History
Pharmanutra SpA
Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
Historical valuation for PHN cannot be conducted due to limitations such as insufficient data or other constraints.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Pharmanutra SpA
Balance Sheet Decomposition
Pharmanutra SpA
Current Assets | 59.6m |
Cash & Short-Term Investments | 21.8m |
Receivables | 26.2m |
Other Current Assets | 11.7m |
Non-Current Assets | 52.2m |
Long-Term Investments | 438k |
PP&E | 25.4m |
Intangibles | 23.2m |
Other Non-Current Assets | 3.1m |
Current Liabilities | 28.3m |
Accounts Payable | 11.7m |
Accrued Liabilities | 3.4m |
Short-Term Debt | 1.7m |
Other Current Liabilities | 11.6m |
Non-Current Liabilities | 28.7m |
Long-Term Debt | 21.2m |
Other Non-Current Liabilities | 7.5m |
Earnings Waterfall
Pharmanutra SpA
Revenue
|
157.8m
EUR
|
Cost of Revenue
|
-6.9m
EUR
|
Gross Profit
|
150.9m
EUR
|
Operating Expenses
|
-115.5m
EUR
|
Operating Income
|
35.4m
EUR
|
Other Expenses
|
-14m
EUR
|
Net Income
|
21.4m
EUR
|
Free Cash Flow Analysis
Pharmanutra SpA
EUR | |
Free Cash Flow | EUR |
PHN Profitability Score
Profitability Due Diligence
Pharmanutra SpA's profitability score is 72/100. The higher the profitability score, the more profitable the company is.
Score
Pharmanutra SpA's profitability score is 72/100. The higher the profitability score, the more profitable the company is.
PHN Solvency Score
Solvency Due Diligence
Pharmanutra SpA's solvency score is 69/100. The higher the solvency score, the more solvent the company is.
Score
Pharmanutra SpA's solvency score is 69/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PHN Price Targets Summary
Pharmanutra SpA
According to Wall Street analysts, the average 1-year price target for PHN is 86.02 EUR with a low forecast of 78.78 EUR and a high forecast of 92.4 EUR.
Dividends
Current shareholder yield for PHN is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one PHN stock under the Base Case scenario is 42.79 EUR.
Compared to the current market price of 54 EUR, Pharmanutra SpA is Overvalued by 21%.